Table 4.
Predictors for IFI during VEN-HMA therapy
| IFI | P | ||
|---|---|---|---|
| Yes | No | ||
| AML setting | .0498 | ||
| Newly diagnosed (n = 55) | 3 (5) | 52 (95) | |
| r/r (n = 64) | 12 (19) | 52 (81) | |
| Patient age, y | .287 | ||
| ≤65 (n = 41) | 7 (17) | 34 (83) | |
| >65 (n = 78) | 8 (10) | 70 (90) | |
| Antifungal prophylaxis | .8262 | ||
| None (n = 25) | 2 (8) | 23 (92) | |
| Micafungin (n =45) | 6 (13) | 39 (87) | |
| Azoles (n = 49) | 7 (14) | 42 (86) | |
| HMA type and schedule | .0536 | ||
| Decitabine | |||
| 5 d (n = 49) | 5 (10) | 44 (90) | |
| 10 d (n = 54) | 5 (9) | 49 (91) | |
| Azacitidine (n = 16) | 5 (31) | 11 (69) | |
| Response to therapy | .0132 | ||
| Yes (n = 68) | 4 (6) | 64 (94) | |
| No (n = 51) | 11 (22) | 40 (78) | |
| Prior alloHCT | .4268 | ||
| Yes (n = 16) | 3 (19) | 13 (81) | |
| No (n = 102) | 12 (12) | 90 (88) | |
| Neutropenia duration, d | .7283 | ||
| ≤30 (n = 24) | 2 (8) | 22 (92) | |
| >30 (n = 76) | 11 (14) | 65 (86) | |
Data are n (%).